{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:30:39Z","timestamp":1790217039226,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.thromres.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T07:57:22Z","timestamp":1709625442000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study"],"prefix":"10.1016","volume":"236","author":[{"given":"O\u011fuzhan","family":"Firat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcmit Yavuz","family":"Malkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutay","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet \u00c7a\u011fkan","family":"Inkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2024.03.003_bb0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740338.2015.997206","article-title":"Tigecycline: a critical safety review","volume":"14","author":"Kaewpoowat","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"9","key":"10.1016\/j.thromres.2024.03.003_bb0010","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.thromres.2024.03.003_bb0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.idcr.2018.01.003","article-title":"Tigecycline-associated hypofibrinogenemia: a case report and review of the literature","volume":"11","author":"Wu","year":"2018","journal-title":"IDCases"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.003_bb0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4274\/tjh.2017.0310","article-title":"A lesser known side effect of tigecycline: hypofibrinogenemia","volume":"35","author":"Duran","year":"2018","journal-title":"Turk. J. Hematol."},{"issue":"43","key":"10.1016\/j.thromres.2024.03.003_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022638","article-title":"Hypofibrinogenemia induced by high-dose tigecycline\u2014case report and review of literature","volume":"99","author":"Fan","year":"2020","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.003_bb0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/08923970902838672","article-title":"Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines","volume":"31","author":"Saliba","year":"2009","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.thromres.2024.03.003_bb0035","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","article-title":"Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline","volume":"89","author":"Pieringer","year":"2010","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.003_bb0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/MEG.0000000000000087","article-title":"Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis","volume":"26","author":"Rossitto","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.thromres.2024.03.003_bb0045","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","article-title":"Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder","volume":"47","author":"Sabanis","year":"2015","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.003_bb0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1248\/cpb.c18-00844","article-title":"A retrospective analysis of the effect of tigecycline on coagulation function","volume":"67","author":"Leng","year":"2019","journal-title":"Chem. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.003_bb0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/jcpt.13250","article-title":"Risk factors for tigecycline-induced hypofibrinogenaemia","volume":"45","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.thromres.2024.03.003_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.943674","article-title":"Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: a multicenter retrospective study in China","volume":"13","author":"Leng","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.thromres.2024.03.003_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2024.03.003_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/JBM.S90693","article-title":"Acquired hypofibrinogenemia: current perspectives","volume":"7","author":"Besser","year":"2016","journal-title":"J. Blood Med."},{"key":"10.1016\/j.thromres.2024.03.003_bb0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/TCRM.S302850","article-title":"Risk factors for tigecycline-associated hypofibrinogenemia","volume":"17","author":"Liu","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.thromres.2024.03.003_bb0080","doi-asserted-by":"crossref","first-page":"1182644","DOI":"10.3389\/fphar.2023.1182644","article-title":"Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone\/sulbactam therapy and other tigecycline-based combination therapies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.003_bb0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.003_bb0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.003_bb0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1378\/chest.09-3081","article-title":"Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators","volume":"139","author":"Decousus","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.003_bb0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.003_bb0105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40121-022-00597-w","article-title":"Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options","volume":"11","author":"Bartal","year":"2022","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/j.thromres.2024.03.003_bb0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2146\/ajhp150894","article-title":"Tigecycline-induced coagulopathy","volume":"74","author":"McMahan","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.003_bb0115","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2006-08-040956","article-title":"Human plasma fibrinogen is synthesized in the liver","volume":"109","author":"Tennent","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2024.03.003_bb0120","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.21037\/tau-22-522","article-title":"Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study","volume":"11","author":"Xie","year":"2022","journal-title":"Transl. Androl. Urol."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.003_bb0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jgh.14876","article-title":"Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand","volume":"35","author":"Warrillow","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.thromres.2024.03.003_bb0130","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2147\/IDR.S339188","article-title":"Comparison of bleeding risk between colistin\u2013tigecycline and colistin\u2013carbapenem treatment regimens: a retrospective cohort study","author":"Huang","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.thromres.2024.03.003_bb0135","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","article-title":"Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients","volume":"76","author":"Hu","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824000744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:19:01Z","timestamp":1717251541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824000744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S0049384824000744"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.003","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}